fig3

From: Mitochondria-targeting amphiphilic polymers enable idebenone to promote neuronal regeneration following spinal cord injury

Figure 3. Pharmacokinetics and spinal cord enrichment of nanoparticles in mice. (A) In vivo imaging of mice at 1, 3, 6, 12, and 24 h after tail vein injection of SP@I-Cy5.5, P@I-Cy5.5, Cy5.5, and PBS; (B) Plasma fluorescence intensity at 0 h, 5 min, 1 h, 3 h, 6 h, 12 h, 24 h, and 48 h after i.v. injection of SP@I-Cy5.5, P@I-Cy5.5, Cy5.5. Statistical significance: SP@I-Cy5.5 vs. P@I-Cy5.5, P < 0.001 (3-48 h); P@I-Cy5.5 vs. Cy5.5, P < 0.001 (3 h), P < 0.001 (6 h), P = 0.0006 (12 h), P = 0.0034 (24 h), P = 0.0022 (48 h). (C) Ex vivo imaging of the spinal cord and brain of mice at 24 h after tail vein injection of SP@I-Cy5.5, P@I-Cy5.5, Cy5.5, and PBS. (D) Quantitative analysis of the spinal cord fluorescence at 24 h. SP@I vs. P@I, P = 0.0013; SP@I vs. Cy5.5, P = 0.0019; SP@I vs. PBS, P = 0.0010. (E) Quantitative analysis of the brain ex vivo imaging. SP@I vs. P@I, P = 0.0048; SP@I vs. Cy5.5, P = 0.0010; SP@I vs. PBS, P = 0.0004. Data are expressed as the mean ± SD (n = 3). PBS: Phosphate buffered saline; SD: standard deviation.